Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
August 26, 2021- Agreement Represents Path to Market for ZYESAMI™, as Time to Treatment is Crucial for Patients
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential...
-
August 24, 2021
NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock. The Company issued to the...
-
August 23, 2021- NRx Pharmaceuticals to lead BriLife Vaccine Trial in Caucasus Region
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports1 in the Israeli media that participants in the BriLife vaccine trial who received the...
-
August 16, 2021- Emergency Use Authorization (EUA) Request for ZYESAMI™ (aviptadil) Pending with United States Food and Drug Administration to Treat Patients Suffering from Critical COVID-19 with Respiratory Failure
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a...
-
August 11, 2021--Company to Host Conference Call August 17, 2021 at 8:30AM ET--
RADNOR, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company, today announced that management will report second...
-
August 10, 2021NRx Advancing Investigational Medicines for Critical COVID-19 and Other Respiratory Conditions, Vaccine to Prevent COVID-19 and Breakthrough Drug for Suicidal Depression and PTSD
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced that the NRx Team, together with Prof Jonathan Javitt, Founder, Chairman and CEO of...
-
August 9, 2021-Dose-Confirmatory Trial Follows Successful Phase 2a Trial
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial of the BriLife™ vaccine against...
-
August 8, 2021
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx's management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference...
-
August 4, 2021- ZYESAMI™ (aviptadil) was awarded Fast Track Designation by the U.S. Food and Drug Administration for the Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome Associated with COVID-19
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI™ (aviptadil), a synthetic form of...
-
July 27, 2021-- More than One Thousand New Cases of COVID-19 Diagnosed Every Day in Georgia, With Increasing Detection of the Delta Variant
NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage, global biopharmaceutical company, today announced that the Nation of Georgia's Prime Minister and Minister of Health have issued an...
Click here to view our corporate presentation or on the image below